Cargando…

Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial

Background: Elevated S100 calcium binding protein B (S100B) levels in systemic circulation may induce neuroinflammation and reflect greater blood–brain barrier (BBB) dysfunction. Neuroinflammation in patients with major depressive disorder (MDD), in turn, may reduce likelihood of improvement with se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jha, Manish K., Minhajuddin, Abu, Gadad, Bharathi S., Chin Fatt, Cherise, Trivedi, Madhukar H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958482/ https://www.ncbi.nlm.nih.gov/pubmed/31861074 http://dx.doi.org/10.3390/ph12040184

Ejemplares similares

Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination
por: Jha, Manish K, et al.
Publicado: (2017)

Psychometric Properties of the Concise Associated Symptom Tracking Scale and Validation of Clinical Utility in the EMBARC Study
por: Minhajuddin, Abu, et al.
Publicado: (2020)

Immune characterization of suicidal behavior in female adolescents
por: Chin Fatt, Cherise R., et al.
Publicado: (2022)

Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory
por: Mason, Brittany L., et al.
Publicado: (2022)

Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale
por: Jha, Manish K, et al.
Publicado: (2017)

Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials
por: Jha, Manish K, et al.
Publicado: (2019)

Leveraging the microbiome to understand clinical heterogeneity in depression: findings from the T-RAD study
por: Chin Fatt, Cherise R., et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on adults with current and prior depression: initial findings from the longitudinal Texas RAD study
por: Czysz, Andrew H., et al.
Publicado: (2021)

Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder
por: Jha, Manish K, et al.
Publicado: (2017)

Can targeted metabolomics predict depression recovery? Results from the CO-MED trial
por: Czysz, Andrew H., et al.
Publicado: (2019)

Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation
por: Jha, Manish K., et al.
Publicado: (2018)

Brain Regulation of Emotional Conflict Predicts Antidepressant Treatment Response for Depression
por: Fonzo, Gregory A., et al.
Publicado: (2019)

Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression
por: Burstein, Or, et al.
Publicado: (2017)

Brain Ventricle and Choroid Plexus Morphology as Predictor of Treatment Response: Findings from the EMBARC Study
por: Murck, Harald, et al.
Publicado: (2023)

Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients
por: Jha, Manish K., et al.
Publicado: (2016)

Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex
por: Tian, Shui, et al.
Publicado: (2019)

PS110. Reversal of stress-induced anhedonia by the multimodel antidepressant, vortioxetine
por: Christensen, AK, et al.
Publicado: (2016)

Different depression: motivational anhedonia governs antidepressant efficacy in Huntington’s disease
por: McLauchlan, Duncan James, et al.
Publicado: (2022)

An electroencephalographic signature predicts antidepressant response in major depression
por: Wu, Wei, et al.
Publicado: (2020)

Correction to: Different depression: motivational anhedonia governs antidepressant efficacy in Huntington's disease
Publicado: (2023)

Differential effects of antidepressants escitalopram versus lithium on Gs alpha membrane relocalization
por: Donati, Robert J, et al.
Publicado: (2015)

Addressing adherence to antidepressant treatment for depression
por: Mayes, Taryn L., et al.
Publicado: (2020)

Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression
por: Bandu, Raju, et al.
Publicado: (2023)

PS176. A functional resonance imaging investigation of escitalopram monotherapy in first episode depression
por: Ravindran, Arun V., et al.
Publicado: (2016)

The genome‐wide expression effects of escitalopram and its relationship to neurogenesis, hippocampal volume, and antidepressant response
por: Powell, Timothy R., et al.
Publicado: (2017)

Methylphenidate augmentation of escitalopram to enhance adherence to antidepressant treatment: a pilot randomized controlled trial
por: Paulus, Martin P., et al.
Publicado: (2021)

Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
por: Sun, Zuoli, et al.
Publicado: (2023)

A review of quetiapine in combination with antidepressant therapy in patients with depression
por: Daly, Ella J, et al.
Publicado: (2007)

Provide optimized antidepressant monotherapy with multiple drugs before considering antidepressant polypharmacy
por: SAAH, Tammy, et al.
Publicado: (2014)

Galanin(1-15) Potentiates the Antidepressant-like Effects Induced by Escitalopram in a Rat Model of Depression
por: García-Durán, Laura, et al.
Publicado: (2021)

Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2023)

Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: A pooled analysis of 4 Chinese clinical trials
por: Li, Guanjun, et al.
Publicado: (2017)

Neurobiological mechanisms of anhedonia
por: Gorwood, Philip
Publicado: (2008)

Anhedonia and Depressive Disorders
por: Serretti, Alessandro
Publicado: (2023)

Study of antinociceptive activity of SSRI (fluoxetine and escitalopram) and atypical antidepressants (venlafaxine and mirtazepine) and their interaction with morphine and naloxone in mice
por: Sikka, Pranav, et al.
Publicado: (2011)

Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants
por: Alkhafaji, Ali A, et al.
Publicado: (2012)

Effect of combination of ketanserin and escitalopram on behavioral anomalies after olfactory bulbectomy: Prediction of quick onset of antidepressant action
por: Pandey, Dilip K., et al.
Publicado: (2014)

PS99. First episode depression and monotherapy with escitalopram: A 16-week, open-label, flexible-dose study
por: Ravindran, Arun V., et al.
Publicado: (2016)

The Differential Relation of Emotional, Physical, and Sexual Abuse Histories to Antidepressant Treatment Remission and Persistence of Anhedonia in Major Depression: A CAN-BIND-1 Report
por: Harkness, Kate L., et al.
Publicado: (2023)

Escitalopram induced mania
por: Parker, Shubangi, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_7l5ek23p5man4m39i60b89dl4d